期刊文献+

瑞舒伐他汀的剂量大小对房颤射频消融术后复发的影响 被引量:2

THE EFFECT OF DIFFERENT DOSES OF ROSUVASTATIN ON THE RECURRENCE OF ATRIAL FIBRILLATION AFTER RADIOFREQUENCY ABLATION
下载PDF
导出
摘要 目的本研究基于房颤与血脂的关系、他汀调脂与抗炎的多效性,评估10mg瑞舒伐他汀对房颤射频消融术后复发的影响。方法收集临沂市人民医院心血管内科收治的阵发性房颤患者50例,随机分为瑞舒伐他汀治疗组(26例)和对照组(24例)。治疗组在服用治疗基础病原有药物的基础上术后即给瑞舒伐他汀10mg,每晚1次口服;对照组只服用治疗基础病的原有药物。术后随访12个月。观察两组患者术后12个月内的C反应蛋白、24h动态心电图、房颤复发情况、药物不良反应及安全性。选取同时期住院的符合纳入标准的50例非房颤患者作为对照,对比分析房颤组同非房颤组血脂(甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、脂蛋白a(Lp(a))水平的变化。结果 1血脂(TG、LDL、HDL、Lp(a))各参数,房颤组与非房颤组比较均降低,差异有统计学意义(P<0.05);2治疗组和对照组术前基础CRP水平差异无统计学意义(P>0.05);治疗组术后12个月CRP减少程度较对照组明显(P<0.05);治疗组和对照组在房颤复发率方面比较差异无显著性(P>0.05)。结论 1房颤患者血脂(TG、LDL、HDL、Lp(a))水平明显低于非房颤患者;2他汀类药物具有调脂外的多效性,即抗炎作用,10mg瑞舒伐他汀能协调其调脂及抗炎功效,对房颤射频消融术后炎症改变的恢复有明显作用;3房颤射频消融术后服用10mg瑞舒伐他汀有减少术后复发率的趋势。 Objective To evaluate the effect of different doses of rosuvastatin on the recurrence of atrial brillation(AF) after radiofrequency ablation based on the relationship between AF and lipids ,pleiotropy of statins in terms of lipid regulation and anti‐inflammatory effect .Methods 50 cases of paroxysmal AF admit‐ted to the Cardiovascular Internal Medicine Department ,Linyi City People&#39;s Hospital ,were randomly di‐vided into the treatment group of 26 cases and the contrast group of 24 cases .The treatment group re‐ceived oral administration of rosuvastatin 10mg each night in addition to the routine therapy , and the contrast group received the routine therapy .In the 12‐month follow‐up surveys ,the content of C‐reactive pro‐tein (CRP) in 12 months ,the 24‐hour dynamic electro‐cardiogram ,the recurrence of AF ,the adverse drug re‐actions and safety were observed .50 non‐AF cases in the same period were chosen as controls .The con‐tents of triglycerides (TG) ,low density lipoprotein (LDL) ,high density lipoprotein (HDL) and lipopro‐tein a (Lp (a)) between AF patients and non‐AF cases were compared .Results The contents of TG ,LDL , HDL and Lp (a) in both groups decreased significantly ( P〈0 .05) .No significant changes occurred in the content of CRP in both groups ( P〉0 .05) .Greater changes occurred in the content of CRP 12 months af‐ter operation in the treatment group than in the contrast group ( P〈0 .05) .No significant changes in the recurrence of AF were found between the two groups ( P 〉0 .05) .Conclusion The contents of TG ,LDL , HDL and Lp (a) are obviously lower in AF patients than in non‐AF cases .Statins shows pleiotropy be‐sides lipid regulation ,10mg of rosuvastatin can coordinate lipid‐regulating and anti‐inflammatory effect and plays a significant role in the recovery of AF after radiofrequency ablation .Taking 10mg of rosuvastatin can reduce the recurrence rate after radiofrequency ablation of AF .
出处 《山东医学高等专科学校学报》 2015年第1期63-67,共5页 Journal of Shandong Medical College
关键词 房颤 射频消融术 瑞舒伐他汀 C反应蛋白 血脂 Atrial fibrillation Radiofrequency ablation Rosuvastatin C-reactive protein Lipid
  • 相关文献

参考文献12

  • 1Annoura M, Ogawa M, Kumagai K, et al. Cholester- ol paradox in patients with paroxysmal atrial fibrilla- tion[J]. Cardiology, 1999, 92:21-27.
  • 2谢咏梅,宝花,金花.他汀类药物在治疗房颤中的作用分析[J].内蒙古医学杂志,2013,45(1):99-100. 被引量:3
  • 3李毅刚,欧阳非凡,陆尚彪,赵美华,王群山,陈书艳.电解剖系统引导下环肺静脉线性消融隔离肺静脉治疗心房颤动[J].中华心律失常学杂志,2005,9(4):277-282. 被引量:7
  • 4Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibril- lation: the APAF Study[J]. J Am Coil, 2006, 48: 2340-2347.
  • 5Stabile G, Bertalia E, Senatore G, et al. Catheter ab- lation treatment in patient with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter ablation for the cure of atri- al fibrillation study) [J].Eur Heart J, 2006,27: 216- 221.
  • 6Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary vein ablation for chronic atrial fibrillation [J].N Engl J Med,2006,354:934-941.
  • 7张健,蒋华,周贤惠,甘天翊,何卫,汤宝鹏,李发鹏,毛婷,李菲.导管射频消融术治疗心房颤动临床研究[J].中华实用诊断与治疗杂志,2012,26(4):387-389. 被引量:9
  • 8Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers [J]. J Intrv Card Electrophysiol, 2005,13 (3) : 181- 193.
  • 9Ganotakis ES, Mikhailidis DP, Vardas PE. Atrial fi brillation,inflammation and statins[J]. Hellenic J Car- diol, 2006,47(2) :51-53.
  • 10梁海雁,骈晶,姚传臣.瑞舒伐他汀对阵发性房颤患者C-反应蛋白、左心房内径及房颤复发率的影响[J].河北医药,2012,34(19):2907-2908. 被引量:9

二级参考文献50

  • 1黄从新,马长生,杨延宗,黄德嘉,张澍,江洪,杨新春,吴书林,马坚,刘少稳,李莉,曹克将,王方正,陈新.心房颤动:目前的认识和治疗建议(二)[J].中华心律失常学杂志,2006,10(3):167-197. 被引量:269
  • 2龚艺,徐劲松,苏海,王卫.他汀类药物对高胆固醇血症患者炎症因子和红细胞膜脂肪酸的影响[J].中国实用内科杂志,2007,27(3):193-195. 被引量:21
  • 3Rosuvastatin Registration Clinical Trial Group.Cardiovascular Institute and Fu Wai Hospital,Peking Union Medical College and Chinese Academy of Medical Science,Beijing 100037,China.瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究[J].中华心血管病杂志,2007,35(3):207-211. 被引量:117
  • 4Nissen SE. High-dose statins in acute coronary syndromes:not just lipid levels [ J ]. JAMA,2004 ;292 ( 11 ) : 1365-7.
  • 5Jones PH, Davidson MH, Stein EA, el al. Comparison of the efficacy and safely of rosuvastatin versus atorvastatin simvastatln and pravastatin across doses( STELLAR Trial ) [J]. Am J Cardiol,2003 ;92(2) :152-60.
  • 6Sukhija R, Fahdi I, Garza L,et al. Inflammatory markers, angiographic severity of coronary artery disease and patient outcome [J]. Am J Cardiol,2007 ;99(7 ) :879-84.
  • 7Anguera I, Mirandar-Guardiola F, Bosch X, et al. Elevation of serum levels of the anti-inflammatory cytokine intedeukin-10 and decreased risk of coronary events in patients with unstable angina[ J ]. Am Heart J,2002;144 (5):811-7.
  • 8Tousoulis D, Antoniades C, Katsi V, et al. The impact of early administration of low-dose atorvastatin treatment of inflammatory process, in patients with unstable angina and low cholesterol level [ J ]. Int J Cardiol, 2006 ; 109 ( 1 ) :48-52.
  • 9Wenger NK, Lewis SJ, Wehy FK, et al. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in woman with stable coronary heart disease in the Treating to New Targets (TNT) Study [J]. Heart, 2008 ;94(4) :434-9.
  • 10Endres M. Statins : potential new indications in inflammatory conditions [J]. Atheroscler Suppl,2006 ;7(1 ) :31-5.

共引文献47

同被引文献35

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部